梓醇对糖尿病小鼠视网膜病变的影响及作用机制

Abstract
Figure/Table
References (29)
Related Citation (15)

Download: PDF (1205 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effects and mechanism of catalpol on retinopathy in mice with diabetes mellitus. Methods A total of 28 SPF KK-Ay diabetic mice aged eight weeks were selected. According to random number table method, they were divided into model group [100 mg/(kg·d) normal saline], Aminoguanidine group [100 mg/(kg·d) Aminoguanidine], catalpol low-dose group [50 mg/(kg·d) catalpol] and catalpol high-dose group [100 mg/(kg·d) catalpol]. SPF C57BL/6J male mice aged eight weeks were selected as blank group [100 mg/(kg·d) normal saline], with seven mice in each group. All the five groups were given intragastric gavage for eight weeks continuously, and their blood glucose levels were monitored before, four and eight weeks after intervention. Eight weeks after administration, pathological changes of retina were observed by HE staining and retinal ganglion cells (RGC) were counted. Serum levels of interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), vascular endothelial growth factor (VEGF), and advanced glycation end product (AGE) in five groups were determined by enzym-linked immunosorbent assay. The expression levels of vascular endothelial cadherin (VE-cadherin), advanced glycolylation end product receptor (RAGE) and phosphorylated nuclear factor-κB p65 (P-NF-κB p65) in retinal cells were determined by Western blot. Results After eight weeks of intervention, the blood glucose levels in the model group was higher than those before interlention, the blood glucose level in the catalpol low-dose group was lower than before, the blood glucose level in the catalpol high-dose group was lower than before and after four weeks and eight weeks of intervention, the differences were statistically significant (all P ＜ 0.05). The blood glucose levels in the model group before intervention, four weeks after intervention and eight weeks intervention were higher than those at the same time points of the blank group， the blood glucose levels in the catalpol low-dose group after eight weeks of intervention were lower than those at the same time point in the model group, the blood glucose levels of catalpol high-dose group after four weeks and eight weeks of intervention were lower than those in the model group at the same time points, with all statistical significance (all P ＜ 0.05). The retinal surface of blank group was smooth, and the structure was clear and complete. In the model group, the retinal structure was loose and the retinal cells were disordered. The retinal structure of catalpol low-dose group was loose and thin. The retinal structure, cell arrangement and retinal thickness were improved in catalpol high-dose group compared with model group. After eight weeks of intervention, the number of RGC in the model group was less than that in the blank group, the number of RGC in catalpol high-dose group was higher than that in model group, and the differences were highly statistically significant (P ＜ 0.01). The levels of IL-1β, TNF-α, VEGF, and AGE in model group were higher than those in blank group, and the levels of IL-1β, TNF-α, VEGF, and AGE in catalpol low-dose and high-dose groups were lower than those in model group, with statistical significance (P ＜ 0.05 or P ＜ 0.01). The expression of VE-cadherin in model group was lower than that in blank group, and the expression of RAGE and P-NF-κB p65 in model group was higher than that in blank group, with statistical significance (all P ＜ 0.05). The expression of VE-cadherin in catalpol low-dose and high-dose groups was higher than that in model group, and the expression of RAGE and P-NF-κB p65 protein in catalpol low-dose and high-dose groups was lower than that in model group, with highly statistical significance (P ＜ 0.01). Conclusion Catalpol can reduce blood glucose and serum inflammatory factor levels, thereby improving retinopathy in mice with diabetes mellitus, and its mechanism may be related to the inhibition of AGE/RAGE/NF-κB signaling pathway.

Key words： Catalpol Diabetic retinopathy Advanced glycation end product Advanced glycolylation end product receptor Phosphorylated nuclear factor-κB p65

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Zhen DU Qiu

Cite this article:

WU Zhen DU Qiu. Effects and mechanism of catalpol on retinopathy in mice with diabetes mellitus[J]. 中国医药导报, 2021, 18(19): 17-21.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I19/17

[1] Yang J，Miao X，Yang FJ，et al. Therapeutic potential of curcumin in diabetic retinopathy（Review）[J]. Int J Mol Med，2021，47（5）：75.
[2] 洪兰，许燕，李立.小柴胡汤合当归芍药散配合激光治疗糖尿病视网膜病变黄斑水肿临床研究[J].实用中医药杂志，2021，37（2）：165-167.
[3] 安娜，刘炳林，韩玲，等.中药新药用于糖尿病视网膜病变临床研究关键技术问题的考虑[J].中国中医眼科杂志，2021，31（1）：63-67.
[4] 何强，钱卫庆，姚年伟，等.地黄梓醇对新生大鼠炎性成骨细胞的保护作用[J].中国组织工程研究，2020，24（29）：4626-4631.
[5] Chen J，Yang Y，Lv Z，et al. Study on the inhibitive effect of Catalpol on diabetic nephropathy [J]. Life Sci，2020， 257：118120.
[6] Bai Y，Zhu R，Tian Y，et al. Catalpol in Diabetes and its Complications：A Review of Pharmacology，Pharmacokinetics，and Safety [J]. Molecules，2019，24（18）：3302.
[7] 孙响波，刘新华，李永伟，等.梓醇对肾纤维化模型大鼠炎症因子表达的影响[J].中医学报，2020，35（11）：2402-2406.
[8] 俞越，李春霞，史春.石斛提取物与糖尿病视网膜病变相关研究进展[J].中国中医眼科杂志，2021，31（3）：215-217.
[9] 谭啸，崔珊珊.激光光凝术治疗糖尿病视网膜病变的临床疗效及其对并发症的防治效果[J].中国现代医生，2021， 59（2）：83-85，89.
[10] Kim HM，Woo SJ. Ocular Drug Delivery to the Retina：Current Innovations and Future Perspectives [J]. Pharmaceutics，2021，13：108.
[11] 郑通美.眼底激光联合康柏西普治疗糖尿病视网膜病变效果分析[J].中国医药科学，2021，11（6）：215-217，228.
[12] 朱慧明，魏刚，张会欣，等.岐黄名目胶囊对糖尿病小鼠视网膜病变及生长因子表达的影响[J].中国全科医学，2012，10（15）：3551-3554.
[13] Wang Y，Lu YH，Tang C，et al. Calcium Dobesilate Restores Autophagy by Inhibiting the VEGF/PI3K/AKT/mTOR Signaling Pathway [J]. Front Pharmacol，2019，10：886.
[14] 王巍，张晓梅，王彬杰，等.ICAM-1和VEGF在KK-Ay糖尿病小鼠视网膜中的表达[J].哈尔滨医科大学学报，2011，45（3）：222-225.
[15] 吴璧，王保华，欧阳静萍.黄芪多糖对遗传性糖尿病kkay小鼠视网膜中TNF-α表达的影响[J].时珍国医国药，2007，18（5）：1031-1032.
[16] 宋茹.明目地黄丸对糖尿病视网膜病变的疗效[J].中医临床研究，2013，5（11）：36-37.
[17] 石瑶瑶，崔玉双，高宏程，等.缝隙连接蛋白43在糖尿病视网膜病变中的作用[J].中国眼耳鼻喉科杂志，2021， 21（2）：144-147.
[18] Liu Y，Wu N. Progress of Nanotechnology in Diabetic Retinopathy Treatment [J]. Int J Nanomedicine，2021， 16：1391-1403.
[19] 张瀚文，石岩.糖尿病视网膜病变与血-视网膜屏障损伤机制研究进展[J].中华中医药学刊，2021，39（3）：105-109.
[20] 张宗金，王悦芬，赵文景，等.基于轴探讨糖尿病肾病中医发病机制及治疗靶点[J].世界中医药，2020，15（23）：3704-3709.
[21] Taurone S，Ralli M，Nebbioso M，et al. The role of inflammation in diabetic retinopathy：a review [J]. Eur Rev Med Pharmacol Sci，2020，24（20）：10319-10329.
[22] 汪佶，夏旭光.糖基化终末产物与糖尿病视网膜病变[J].国际眼科杂志，2009，9（2）：328-329.
[23] 李秀，罗蓉，李健，等.小胶质细胞在糖尿病视网膜病变中的作用[J].中华糖尿病杂志，2021，13（3）：277-281.
[24] 刘莉，张风梅，李昊洋.益气活血通络方治疗糖尿病视网膜病变临床研究[J].中医学报，2018，33（2）：227-231.
[25] 徐赵钕，章仕淼，刘玲玲.明目地黄丸对糖尿病视网膜病变大鼠细胞自噬及Akt-mTOR通路的影响[J].中国医药导报，2018，15（20）：16-20，32.
[26] Ra H，Lee A，Lee J，et al. Cytokines associated with hemorrhage in proliferative diabetic retinopathy [J]. Int Ophthalmol，2021，41（5）：1845-1853.
[27] 闫配，张晓红，张莉，等.HMW-ADP、TNF-α、VEGF与糖尿病视网膜病变的关系研究[J].中国医药导报，2019，16（9）：106-109.
[28] 刘昳，袁进.核转录因子-кB在氧诱导血管增殖性视网膜病变小鼠中的表达[J].眼科新进展，2014，34（12）：1101-1104.
[29] 李敏，莫诗雯，李伊，等.血-视网膜屏障损伤的机制及治疗对策[J].国际眼科杂志，2020，20（11）：1902-1906.